Efficacy and safety of lenalidomide in HIV-associated cryptococcal meningitis patients with persistent intracranial inflammation: an open-label, single-arm, prospective interventional study

Table 3 Neuroimaging characteristics of participants

Cranial MRI	Baseline	Week 24	P value*
Lesion location
Meninges, number (%)	10 (71.4)	2 (14.3)	0.008
Brain parenchyma, number (%)	3 (21.4)	1 (7.1)	0.500
Cerebral white matter, number (%)	5 (35.7)	3 (21.4)	0.500
Basal ganglia, number (%)	4 (28.6)	3 (21.4)	> 0.999
Lesion nature
Inflammation, number (%)	10 (71.4)	2 (14.3)	0.008
Encephalomalacia, number (%)	2 (14.3)	2 (14.3)	> 0.999
Hemorrhagic lesion, number (%)	1 (7.1)	0 (0)	> 0.999
Cerebral ischemia, number (%)	4 (28.6)	1 (7.1)	0.250
Unidentified lesion, number (%)	3 (21.4)	3 (21.4)	> 0.999

Data show that the number of lesions was not decreasing after 24 weeks of treatment with lenalidomide. *P value was determined by the McNemar test

ISSN: 1742-2094